These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7542147)

  • 41. Routine assessment of amniotic fluid alpha-Fetoprotein in early second-trimester amniocentesis is no longer justified.
    Widlund KF; Gottvall T
    Acta Obstet Gynecol Scand; 2007; 86(2):167-71. PubMed ID: 17364279
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alpha-fetoprotein detection of neural tube defects and the impact of standard ultrasound.
    Dashe JS; Twickler DM; Santos-Ramos R; McIntire DD; Ramus RM
    Am J Obstet Gynecol; 2006 Dec; 195(6):1623-8. PubMed ID: 16769022
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Maternal serum triple analyte screening in pregnancy.
    Graves JC; Miller KE; Sellers AD
    Am Fam Physician; 2002 Mar; 65(5):915-20. PubMed ID: 11898965
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Prenatal screening for major fetal defects by using of maternal serum markers].
    Bao P; Wu Y; Gu Q
    Zhonghua Fu Chan Ke Za Zhi; 1997 Nov; 32(11):649-51. PubMed ID: 9639762
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Major fetal abnormalities associated with positive screening tests for Smith-Lemli-Opitz syndrome (SLOS).
    Craig WY; Haddow JE; Palomaki GE; Roberson M
    Prenat Diagn; 2007 May; 27(5):409-14. PubMed ID: 17286308
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Maternal serum screening and trisomy 16 confined to the placenta.
    Groli C; Cerri V; Tarantini M; Bellotti D; Jacobello C; Gianello R; Zanini R; Lancetti S; Zaglio S
    Prenat Diagn; 1996 Aug; 16(8):685-9. PubMed ID: 8878276
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MRCOG. Screening for fetal abnormalities.
    Smith NC
    Br J Hosp Med; 1996 Jun 5-18; 55(11):679-82. PubMed ID: 8793130
    [No Abstract]   [Full Text] [Related]  

  • 48. Screening for open neural-tube defects in England and Wales.
    Wald N; Cuckle HS; Harwood CA
    Br Med J; 1979 Aug; 2(6185):331. PubMed ID: 89884
    [No Abstract]   [Full Text] [Related]  

  • 49. Biochemical screening for chromosomal disorders and neural tube defects (NTD): is adjustment of maternal alpha-fetoprotein (AFP) still appropriate in insulin-dependent diabetes mellitus (IDDM)?
    Sancken U; Bartels I
    Prenat Diagn; 2001 May; 21(5):383-6. PubMed ID: 11360279
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevention of Down syndrome: the Jerusalem experience.
    Bach G; Ben-Neriah Z; Sagi M
    Isr J Med Sci; 1993 Aug; 29(8):468-70. PubMed ID: 7691779
    [No Abstract]   [Full Text] [Related]  

  • 51. At increased risk: neural tube defect relatives.
    Hecht F; Hecht BK; Wagner RC; Szucs SC
    Ariz Med; 1983 Nov; 40(11):759-62. PubMed ID: 6197956
    [No Abstract]   [Full Text] [Related]  

  • 52. [Prioritization and the "triple"-test in prenatal diagnosis].
    Pedersen KM
    Ugeskr Laeger; 1999 Dec; 161(50):6901. PubMed ID: 10643374
    [No Abstract]   [Full Text] [Related]  

  • 53. Routine ultrasonography compared with maternal serum alpha-fetoprotein for neural tube defect screening.
    Norem CT; Schoen EJ; Walton DL; Krieger RC; O'Keefe J; To TT; Ray GT
    Obstet Gynecol; 2005 Oct; 106(4):747-52. PubMed ID: 16199631
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prenatal diagnosis using the triple test.
    Palka G; Guanciali Franchi P; Papponetti M; Marcuccitti J; Morizio E; Calabrese G; Stuppia L; Di Ilio C
    Minerva Ginecol; 1998 Oct; 50(10):411-5. PubMed ID: 9866951
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The triple-serum test for detection of Down syndrome and neural tube defects; the problem of a risk assessment test].
    van den Boer-van den Berg JM; Dupuis HM
    Ned Tijdschr Geneeskd; 1993 Jun; 137(26):1286-9. PubMed ID: 7688445
    [No Abstract]   [Full Text] [Related]  

  • 56. [Triple test: problem or enhancement of prenatal diagnosis].
    Rauskolb R; Engel W
    Z Geburtshilfe Neonatol; 1995; 199(3):91. PubMed ID: 7553260
    [No Abstract]   [Full Text] [Related]  

  • 57. Insulin-dependent diabetes mellitus and prenatal screening results: current experience from a regional screening programme.
    Crossley JA; Berry E; Aitken DA; Connor JM
    Prenat Diagn; 1996 Nov; 16(11):1039-42. PubMed ID: 8953638
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Benefits of maternal serum alpha-fetoprotein testing.
    Dyson RD
    Am Fam Physician; 1996 Nov; 54(6):1890, 1893. PubMed ID: 8900347
    [No Abstract]   [Full Text] [Related]  

  • 59. [How women cope with the results of maternal serum screening for fetal neural tube defects and Down syndrome].
    Kamerbeek LI; Roelofsen EE; Beekhuis JR; Tijmstra T; Mantingh A
    Ned Tijdschr Geneeskd; 1993 Jun; 137(26):1308-11. PubMed ID: 7688449
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Maternal serum screening for birth defects: results of a Connecticut regional program.
    Benn PA; Horne D; Craffey A; Collins R; Ramsdell L; Greenstein R
    Conn Med; 1996 Jun; 60(6):323-7. PubMed ID: 8706425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.